Start-up to develop new treatment for heart failure
Our Department exploits their academic findings towards rational therapy development for genetic and acquired forms of heart failure in the Dutch spin-off company Mirabilis Therapeutics BV that was founded in 2015.
Mirabilis Therapeutics BV is a drug development company dedicated to the discovery and development of innovative products in the field of cardiovascular diseases.
For more information on Mirabilis Therapeutics BV, please visit: www.mirabilis-therapeutics.com
Also read
-
Professor Thomas Cleij reappointed as Dean of the Faculty of Science and Engineering
The Executive Board of Maastricht University has reappointed Prof. Dr. Thomas Cleij as Dean of the Faculty of Science and Engineering. Thomas will continue to lead the faculty until March 2031.
-
National inspiration guide on societal engagement training programmes features FSE’s SciCom Incubator programme
A new inspiration guide shows how training helps researchers incorporate societal engagement in their careers, building on examples implemented at five different universities.
-
Suzie: "What is happening in my home country keeps me up at night"
From Maastricht, Suzie Nzekui is fighting for women in her home country, Cameroon. With her feminist women's collective and Master’s in Systems Biology and Bioinformatics, she is working to improve healthcare for women.
